As a precautionary measure to assure supply, Pfizer Canada (PFE), the manufacturer of Mylan’s (MYL +0.9%) emergency allergic reaction med EpiPen (epinephrine injection), will take over distribution as it tries to sidestep a potential shortage of the 0.3 mg formulation there. At present, it has a supply of product and shipments are continuing, adding that the issue should be resolved by early October.
EpiPen Jr (0.15 mg) is not affected.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.